Concurrent chemoradiotherapy (cCRT)

DRUG7 trials

Conditions

Advanced Esophageal Squamous Cell CarcinomaCarcinoma, Non-Small-Cell LungEsophageal Squamous Cell CancerLocally Advanced Non-Small Cell Lung CancerNasopharyngeal Cancinoma (NPC)Nasopharyngeal CarcinomaNon-Small Cell Lung CancerQuality of Life

Phase 1

Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer

RecruitingNCT07632365

Shanghai Chest HospitalLocally Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Unresectable Stage III NSCLC

Start: 2022-10-09End: 2028-12-31Target: 108Updated: 2026-07-23

Phase 2

Endostar in Combination With Chemoradiotherapy in Patient With Advanced Non-small Cell Lung Cancer

NCT03588494

Afﬁliated Hospital of North Sichuan Medical CollegeQuality of Life

Start: 2018-08-01End: 2021-09-01Target: 318Updated: 2018-07-17

GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma

RecruitingNCT06455410

Sun Yat-sen UniversityNasopharyngeal Carcinoma

Start: 2024-06-18End: 2028-06-18Target: 216Updated: 2024-06-25

Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma.

Not yet recruitingNCT07469241

Fudan UniversityAdvanced Esophageal Squamous Cell Carcinoma, Unresectable Esophageal Squamous Cell Carcinoma

Start: 2026-03-10End: 2029-06-30Target: 50Updated: 2026-03-13

Phase 3

A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer

TerminatedNCT03745222

CelgeneCarcinoma, Non-Small-Cell Lung

Start: 2019-05-22End: 2019-06-26Updated: 2020-07-15

Adaptive Immunotherapy for Nasopharyngeal Carcinoma

RecruitingNCT07154069

Sun Yat-sen UniversityNasopharyngeal Cancinoma (NPC)

Start: 2025-11-13End: 2033-09-30Target: 802Updated: 2025-11-25

Unknown Phase

Retlirafusp Alfa Combined With Chemoradiotherapy in Unresectable ESCC

Not yet recruitingNCT07769866

RenJi HospitalEsophageal Squamous Cell Cancer

Start: 2026-09-01End: 2030-06-30Target: 68Updated: 2026-08-18

2020-10-0112 citations

Antibodies to watch in 2020.

2020-01-01328 citations

Tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy for newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) in a phase III study (RATIONALE 001).

Journal of Clinical Oncology2019-05-202 citations

RATIONALE 001: Tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC)

Annals of Oncology2019-04-01